Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone Disease
Kyowa Kirin Co., Ltd. today announced the publication of new data highlighting the sustained benefits of treatment with CRYSVITA ® in adults with X-linked hypophosphataemia, a rare genetic metabolic bone disease. Lead author Pr Karine Briot, Hôpital Cochin, Paris, France said:“ The study highlights the many physical challenges faced by adult patients with...
Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced detailed data from a Phase 2 study of KHK4083/AMG 451 will be highlighted in late-breaking oral presentation at the European Academy of Dermatology and Venereology 30 th Virtual Congress to be held...